Some 800 patients a year are being refused funding for drugs that can tackle – but not cure – rare or advanced cancers, according to a survey by the Rarer Cancers Forum, a patient group.

The survey also reveals the apparently random local process that decides both whether patients will receive drug treatment for their ­condition and how they can access it.